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Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183S178(HSCT). Outcomes with myelaoblative conditioning have
been surprisingly poor with almost 1/3 of patients suc-
cumbing to early transplant related mortality (TRM). Most of
the fatalities occur due to cardiopulmonary failure. Mortality
is higher than that in other immunodeﬁciency syndromes,
however the reasons for this increased toxicity are unclear.
We hypothesized that prolonged steroid exposure during
HLH therapy may cause the development of cardiac hyper-
trophy. Compromised cardiac reserve could contribute to
poor outcome because of the multiple physiological stressors
associated with transplant.
We reviewed the records of 11 consecutive children under-
going HSCT at our institution from January 2004- December
2012. The age at diagnosis ranged from birth to 60 (median
2.5) months and the age at HSCT from 6-70 (median 9)
months. 8/11 had identiﬁed genetic defects (5 perforin, 2
MUNC, 1 Griscelli). All 11 received pre-HSCT therapy with
etoposide, cyclosporin and dexamethasone. 10/11 were in
complete disease remission at the time of HSCT. Conditioning
was fully ablative in 9/11(Bu, Cy, VP, ATG) and reduced in-
tensity in 2 (Flu/campath). 6 received marrow as stem cell
source. Donors were matched sibling in 1, and unrelated
donor in 5. 5 received unrelated umbilical cord. All patients
except the sibling donor received methylprednisonole at 1-2
mg/kg/day as GVHD prophylaxis. 3 had acute GVHD and
received additional therapy with high dose (>2 mg/kg/day)
steroids.
Pre transplantation echocardiograms were accessible for 6
patients; none had evidence of LVH. Post transplantation
echocardiograms were reviewed for all patients. 7/11 (64%)
never evidenced LVH at any point post-HSCT. TRM in this
group was 3/7 (42%) due to multi-organ system failure
(MOSF) (2) and adenovirus infection (1). 4/11 patients (36%)
developed LVH 1 - 18weeks post-HSCT. TRMwas 100% in this
group, higher than thosewithout LVH (p¼0.58) and all due to
MOSF. Infectious agents were only identiﬁed in 1/4 (adeno /
EBV) and recurrent HLH in one.
In light of these ﬁndings, particular attention to cardiac status
in patients with HLH is highly recommended. Further inves-
tigation is needed to identify pre and post SCT factors
contributing to cardiac hypertrophy. This will allow both pre-
ventativemeasures to be developed and optimalmanagement
to be provided when these patients become critically ill.262
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Chromosome 7 deletions are adverse prognostic factors asso-
ciated with worse outcomes in patients with hematologicalmalignancies. However there are few outcome data for he-
matopoietic stem cell transplant (HSCT) in pediatric patients
with hematological malignancies and chromosome 7 de-
letions. We now describe the outcome in 40 patients with
chromosome 7 abnormalities (ALL, n¼13, AML, n¼11, MDS,
n¼14 and JMML, n¼2) who received an allogeneic HSCTat our
institution between 2001-2013. The median age at the time of
transplant was 9 years (range: 1-18 years). There were 23 pa-
tients with monosomy 7, 12 with 7q- and 5 with 7p-. At the
time of transplant, 16 of the 24 patients with acute leukemia
(ALL/AML) were in CR (9-CR1, 6-CR-2, 1-CR3) and 8/24 had
active disease (3with primary refractory disease, 5 in relapse).
All patients with ALL (13/13),10/11 patientswith AML and 1 /2
patients with JMML received chemotherapy prior to trans-
plant, while patients with MDS received no prior therapy. Pa-
tients received HSCT from MRD (10), MUD (17), MMUD (4) or
haploidentical donors (9). The median time to engraftment
was 19 days (95%CI: 17-20 days). With a median follow up of
857 days (range 5 -4099 days), the 3-year overall survival (OS)
and disease free survival (DFS) for the entire cohort was 60%
and 53%, respectively. The OS and DFS correlated with the
underlying diagnosis with MDS patients having better 3-year
OS andDFS (OS:MDS (77%), AML (36%), ALL (67%), JMML (50%)
and DFS: MDS (64%), AML (36%), ALL (58%), JMML (50%)
Outcome was not signiﬁcantly affected by the type of chro-
mosome 7 deletion (3-year OS: monosomy 7 (59%), 7q- (53%),
7p- (80%), p ¼ 0.528). Upon further subdivision by diagnosis,
patients with MDS that had associated monosomy 7 had
signiﬁcantly better OS compared to patients with AML and
monosomy 7 as well as ALL and monosomy 7 (p ¼ 0.014 and
p ¼ 0.029, respectively). Patients with MDS and associated
chromosome 7 deletions, in particular monosomy 7, may
achieve very good OS and DFS after HSCT. In contrast, patients
with AML do not fare as well after HSCT.263
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Dyskeratosis congenita is a rare inherited bone marrow
failure and cancer predisposition syndrome with multi-
system involvement. While allogeneic hematopoietic stem
cell transplant (HSCT) can cure the bone marrow failure,
reported survival is low, with patients suffering unusual
complications post HSCT. We describe the long term
outcome in 6 patients with mutation proven DC following an
allo-HSCT at our institution between 1997e2011. To our
knowledge this is the ﬁrst report to begin to correlate ge-
notype to phenotype post HSCT. The median age was 4 years
(range: 2e13). 4 patients had mutations in the TINF2 gene, 1
in DKC1 and 1 had a homozygous TERTmutation. 4/6 patients
received reduced intensity conditioning (RIC) regimens and
